TrivarX（MDBI.F）株式概要TrivarX Limitedは医療技術企業で、オーストラリアと米国で行動健康状態のスクリーニングと診断のためのAI主導の科学的根拠に基づく機器の開発に従事している。 詳細MDBI.F ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析収益が 100 万ドル未満 ( A$-95K )過去1年間で株主の希薄化は大幅に進んだ 株式の流動性は非常に低い 意味のある時価総額がありません ( $24M )すべてのリスクチェックを見るMDBI.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.0026該当なし内在価値ディスカウントEst. Revenue$PastFuture-15m4m2016201920222025202620282031Revenue AU$0.6Earnings AU$0.07AdvancedSet Fair ValueView all narrativesTrivarX Limited 競合他社Firefly NeuroscienceSymbol: NasdaqCM:AIFFMarket cap: US$25.3mSafeSpace GlobalSymbol: OTCPK:SSGCMarket cap: US$24.7mScienture HoldingsSymbol: NasdaqCM:SCNXMarket cap: US$16.3mDarioHealthSymbol: NasdaqCM:DRIOMarket cap: US$55.1m価格と性能株価の高値、安値、推移の概要TrivarX過去の株価現在の株価AU$0.002652週高値AU$0.02452週安値AU$0.0025ベータ0.831ヶ月の変化4.00%3ヶ月変化n/a1年変化n/a3年間の変化-83.75%5年間の変化-97.83%IPOからの変化-99.90%最新ニュースお知らせ • Dec 19TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 437,725,337 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listingお知らせ • Oct 27TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listingお知らせ • Oct 16TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listingお知らせ • Sep 26TrivarX Limited, Annual General Meeting, Nov 21, 2025TrivarX Limited, Annual General Meeting, Nov 21, 2025. Location: at the companys registered office, at 647 beaufort street, mount lawley, Australiaお知らせ • May 20TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listingお知らせ • Mar 17TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listing最新情報をもっと見るRecent updatesお知らせ • Dec 19TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 437,725,337 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listingお知らせ • Oct 27TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listingお知らせ • Oct 16TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listingお知らせ • Sep 26TrivarX Limited, Annual General Meeting, Nov 21, 2025TrivarX Limited, Annual General Meeting, Nov 21, 2025. Location: at the companys registered office, at 647 beaufort street, mount lawley, Australiaお知らせ • May 20TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listingお知らせ • Mar 17TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listingお知らせ • Oct 09TrivarX Limited, Annual General Meeting, Nov 28, 2024TrivarX Limited, Annual General Meeting, Nov 28, 2024. Location: 647 beaufort street, mount lawley, western australia., western australia. Australiaお知らせ • Sep 25TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024TrivarX Limited announced that it has strengthened the composition of its Board with the appointment of Mr. John H. Mathias II as a Non-executive Director, effective 1 October 2024. Mr. Mathias is an accomplished healthcare focused operations and business development executive, with a clinical background in respiratory care. He has a demonstrated track record of success over a 30-year career in the US healthcare industry. Currently, he holds the role of Chief Development Officer at Medbridge Healthcare. MedBridge also has a number of professional partnerships that support adjacent services including hospital readmission reduction programs (HRRP), product and drug research, occupational health, professional services and therapeutic sleep offerings. As CDO, he plays a central role in building partnerships with stakeholders across the US healthcare system in the field of sleep medicine including hospitals, medical research institutions, clinical partnerships, and insurance companies. Prior to his role as CDO, Mr. Mathias also served as Chief Operating Officer and President of Sleep Services of America Inc., an entity of Johns Hopkins Health System, where he managed operations for sleep diagnostics and therapeutic coordination, oversaw strategic M&A and led a business turnaround which returned the division to profitability. Throughout his career, Mr. Mathias has been recognised for building and leading high-performing healthcare managers and sales teams and implementing strategic business plans to drive consistent growth in revenue and margin levels. With direct experience across several US healthcare industries, his core areas of expertise include contract management services for sleep and respiratory services, along with acute care hospital operations and developing improved patient solutions in the aged care industry. Mr. Mathias' appointment provides the Board with additional depth and expertise as it moves from clinical development towards regulatory approval and commercialisation for its proprietary MEB-001 algorithm with the effective screening of a current Major Depressive Episode (cMDE) in the US market.お知らせ • May 02TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 70,970,745 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,029,255 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Transaction Features: Subsequent Direct Listingお知らせ • Oct 06Medibio Limited, Annual General Meeting, Nov 29, 2023Medibio Limited, Annual General Meeting, Nov 29, 2023, at 09:00 W. Australia Standard Time. Location: COMO The Treasury, Executive Boardroom, 1 Cathedral Avenue, Perth WA 6000 Australiaお知らせ • Feb 18Medibio Limited Appoints Christopher Ntoumenopoulos as DirectorMedibio Limited announced the appointment of Christopher Ntoumenopoulos as Director of the company. The date of appointment is 15 February 2023.株主還元MDBI.FUS Healthcare ServicesUS 市場7D0%2.6%1.0%1Yn/a-38.2%28.7%株主還元を見る業界別リターン: MDBI.FがUS Healthcare Services業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: MDBI.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is MDBI.F's price volatile compared to industry and market?MDBI.F volatilityMDBI.F Average Weekly Movementn/aHealthcare Services Industry Average Movement10.5%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: MDBI.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のMDBI.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト1987n/an/atrivarx.comTrivarX Limitedは医療技術企業で、オーストラリアと米国で行動健康状態のスクリーニングと診断のためのAI主導の科学的根拠に基づく機器の開発に従事している。同社は、企業向け健康製品を通じて企業向けの精神的健康ソリューションを提供し、ヘルスケアプロバイダー市場向けの製品を開発している。同社は以前はMedibio Limitedとして知られていたが、2023年10月にTrivarX Limitedに社名を変更した。TrivarX Limitedは1987年に設立され、オーストラリアのマウント・ローリーに本社を置いている。もっと見るTrivarX Limited 基礎のまとめTrivarX の収益と売上を時価総額と比較するとどうか。MDBI.F 基礎統計学時価総額US$23.84m収益（TTM）-US$1.50m売上高(TTM)n/a-350.9xP/Sレシオ-15.9xPER（株価収益率MDBI.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MDBI.F 損益計算書（TTM）収益-AU$95.36k売上原価-AU$7.69k売上総利益-AU$87.67kその他の費用AU$2.02m収益-AU$2.11m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.0018グロス・マージン91.94%純利益率2,213.15%有利子負債／自己資本比率0%MDBI.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 01:27終値2026/05/06 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋TrivarX Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Stuart RobertsPitt Street Research Pty Ltd.
お知らせ • Dec 19TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 437,725,337 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 27TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 16TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
お知らせ • Sep 26TrivarX Limited, Annual General Meeting, Nov 21, 2025TrivarX Limited, Annual General Meeting, Nov 21, 2025. Location: at the companys registered office, at 647 beaufort street, mount lawley, Australia
お知らせ • May 20TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listing
お知らせ • Mar 17TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listing
お知らせ • Dec 19TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 437,725,337 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 27TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 16TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
お知らせ • Sep 26TrivarX Limited, Annual General Meeting, Nov 21, 2025TrivarX Limited, Annual General Meeting, Nov 21, 2025. Location: at the companys registered office, at 647 beaufort street, mount lawley, Australia
お知らせ • May 20TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listing
お知らせ • Mar 17TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 09TrivarX Limited, Annual General Meeting, Nov 28, 2024TrivarX Limited, Annual General Meeting, Nov 28, 2024. Location: 647 beaufort street, mount lawley, western australia., western australia. Australia
お知らせ • Sep 25TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024TrivarX Limited announced that it has strengthened the composition of its Board with the appointment of Mr. John H. Mathias II as a Non-executive Director, effective 1 October 2024. Mr. Mathias is an accomplished healthcare focused operations and business development executive, with a clinical background in respiratory care. He has a demonstrated track record of success over a 30-year career in the US healthcare industry. Currently, he holds the role of Chief Development Officer at Medbridge Healthcare. MedBridge also has a number of professional partnerships that support adjacent services including hospital readmission reduction programs (HRRP), product and drug research, occupational health, professional services and therapeutic sleep offerings. As CDO, he plays a central role in building partnerships with stakeholders across the US healthcare system in the field of sleep medicine including hospitals, medical research institutions, clinical partnerships, and insurance companies. Prior to his role as CDO, Mr. Mathias also served as Chief Operating Officer and President of Sleep Services of America Inc., an entity of Johns Hopkins Health System, where he managed operations for sleep diagnostics and therapeutic coordination, oversaw strategic M&A and led a business turnaround which returned the division to profitability. Throughout his career, Mr. Mathias has been recognised for building and leading high-performing healthcare managers and sales teams and implementing strategic business plans to drive consistent growth in revenue and margin levels. With direct experience across several US healthcare industries, his core areas of expertise include contract management services for sleep and respiratory services, along with acute care hospital operations and developing improved patient solutions in the aged care industry. Mr. Mathias' appointment provides the Board with additional depth and expertise as it moves from clinical development towards regulatory approval and commercialisation for its proprietary MEB-001 algorithm with the effective screening of a current Major Depressive Episode (cMDE) in the US market.
お知らせ • May 02TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 70,970,745 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,029,255 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 06Medibio Limited, Annual General Meeting, Nov 29, 2023Medibio Limited, Annual General Meeting, Nov 29, 2023, at 09:00 W. Australia Standard Time. Location: COMO The Treasury, Executive Boardroom, 1 Cathedral Avenue, Perth WA 6000 Australia
お知らせ • Feb 18Medibio Limited Appoints Christopher Ntoumenopoulos as DirectorMedibio Limited announced the appointment of Christopher Ntoumenopoulos as Director of the company. The date of appointment is 15 February 2023.
